marijuana stocks

Form 8-K for TWO RIVERS WATER & FARMING CO

29-Dec-2014

Regulation FD Disclosure, Financial Statements and Exhibits

ITEM 7.01 Regulation FD DisclosurePress Release

The information in this Item 7.01 of this Current Report is furnished pursuant to Item 7.01 and shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act regardless of any general incorporation language in such filing.

Two Rivers Water & Farming Company announced today it has begun construction of its first greenhouse, which is leased to a licensed marijuana grower, through a majority owned subsidiary, GrowCo, Inc.

The text of the press release is attached herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits(d) Exhibits.The following is a complete list of exhibits filed as part of this Report. Exhibit numbers correspond to the numbers in the exhibit table of Item 601 of Regulation S-K.

Exhibit No. Description
99.1 Press release dated December 29, 2014* *Filed herewith

 


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Canopy Growth Corporation (CGC) KICKS OFF THE NEW YEAR WITH NEW PRODUCTS

CANOPY GROWTH KICKS OFF THE NEW YEAR WITH NEW PRODUCTS FROM TWEED,…

Village Farms International, Inc. (VFF) Michael DeGiglio to Host Reddit AMA on Thursday, January 13 at 6 p.m. ET

Village Farms International’s Michael DeGiglio and Pure Sunfarms’ Mandesh Dosanjh to Host…

$CANV CEO is Keeping You Updated!

CannaVEST Corp. CEO Releases Letter to Stockholders and Customers Regarding Report Issued…

AbbVie Inc. (ABBV) Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn’s Disease

AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn’s Disease…